Nabriva Therapeutics (NASDAQ:NBRV) Research Coverage Started at StockNews.com
Nabriva Therapeutics (NASDAQ:NBRV) Research Coverage Started at StockNews.com
Equities researchers at StockNews.com started coverage on shares of Nabriva Therapeutics (NASDAQ:NBRV – Get Rating) in a research report issued to clients and investors on Thursday. The firm set a "hold" rating on the biotechnology company's stock.
StockNews.com的股票研究人员开始报道以下股票 Nabriva Therapeutics（纳斯达克股票代码：NBRV — 获取评级） 在周四发布给客户和投资者的研究报告中。该公司对这家生物技术公司的股票设定了 “持有” 评级。
Separately, Northland Securities cut shares of Nabriva Therapeutics from an "outperform" rating to an "underperform" rating in a research note on Friday, January 6th.
另外，Northland Securities在1月6日星期五的一份研究报告中将Nabriva Therapeutics的股票从 “跑赢大盘” 评级下调至 “表现不佳”。
Nabriva Therapeutics Stock Up 10.7 %
Nabriva Therapeutics股票上涨10.7％
NBRV opened at $1.76 on Thursday. The firm's 50-day simple moving average is $1.81 and its 200-day simple moving average is $3.47. The company has a debt-to-equity ratio of 0.02, a quick ratio of 1.40 and a current ratio of 2.20. Nabriva Therapeutics has a twelve month low of $1.22 and a twelve month high of $13.50. The firm has a market cap of $53.93 million, a price-to-earnings ratio of -0.09 and a beta of 1.67.
NBRV周四开盘价为1.76美元。该公司的50天简单移动平均线为1.81美元，其200天简单移动平均线为3.47美元。该公司的债务与权益比率为0.02，速动比率为1.40，流动比率为2.20。Nabriva Therapeutics创下十二个月低点1.22美元，十二个月高点为13.50美元。该公司的市值为5,393万美元，市盈率为-0.09，beta值为1.67。
Institutional Inflows and Outflows
机构流入和流出
An institutional investor recently raised its position in Nabriva Therapeutics stock. Renaissance Technologies LLC raised its holdings in Nabriva Therapeutics plc (NASDAQ:NBRV – Get Rating) by 102.1% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 795,938 shares of the biotechnology company's stock after acquiring an additional 402,144 shares during the period. Renaissance Technologies LLC owned about 0.13% of Nabriva Therapeutics worth $145,000 at the end of the most recent quarter. 0.23% of the stock is currently owned by hedge funds and other institutional investors.
一位机构投资者最近提高了其在Nabriva Therapeutics股票中的头寸。Renaissance Technologies LLC在向美国证券交易委员会提交的最新13F表文件中显示，该公司在第二季度将其在Nabriva Therapeutics plc（纳斯达克股票代码：NBRV — 获取评级）的持股量提高了102.1％。该基金在此期间又收购了402,144股股票后，拥有这家生物技术公司的795,938股股票。截至最近一个季度末，Renaissance Technologies LLC拥有Nabriva Therapeutics约0.13％的股份，价值14.5万美元。该股票目前由对冲基金和其他机构投资者持有。
Nabriva Therapeutics Company Profile
纳布里瓦疗法公司简介
(Get Rating)
（获取评分）
Nabriva Therapeutics Plc is a biopharmaceutical company, which engages in the research, development, and commercialization of novel anti-infective agents to treat serious infections. Its product pipeline includes Lefamulin, CONTEPO, and BC-7013. The company was founded in October 2005 and is headquartered in Dublin, Ireland.
Nabriva Therapeutics Plc是一家生物制药公司，从事治疗严重感染的新型抗感染药物的研究、开发和商业化。其产品线包括Lefamulin、CONTEPO 和 BC-7013。该公司成立于 2005 年 10 月，总部位于爱尔兰都柏林。
Read More
阅读更多
- Get a free copy of the StockNews.com research report on Nabriva Therapeutics (NBRV)
- Bed Bath & Beyond Is Circling the Drain
- Allegro Microsystems Is A Well-Positioned Semiconductor Stock
- Scotts Miracle-Gro Hits Bottom, Reversal In Play
- Altria is a Great Recession Stock, Long-Term Outlook Uncertain
- Novavax Shares Jumped in January While Others Slipped
- 免费获取 StockNews.com 关于 Nabriva Therapeutics (NBRV) 的研究报告
- Bed Bath & Beyond 正在排水管中盘旋
- Allegro Microsystems 是一家定位良好的半导体
- Scotts Miracle-Gro 触底，在比赛中逆转
- 奥驰亚是大萧条股票，长期前景不确定
- Novavax股价在1月份上涨，而其他股则下滑
Receive News & Ratings for Nabriva Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接收 Nabriva Therapeutics 每日的新闻和评级 -在下面输入您的电子邮件地址，通过Marketbeat.com的免费每日电子邮件时事通讯接收Nabriva Therapeutics及相关公司的最新新闻和分析师评级的简明每日摘要。
译文内容由第三方软件翻译。